Corporate guarantee, section 14A limits and research deduction rules shaped the tax treatment of key business claims.

Corporate guarantee to an associated enterprise was treated as not warranting transfer pricing adjustment where no fresh guarantee, cost, or economic sacrifice was shown. Interest disallowance for alleged diversion of borrowed funds failed because the advances were commercially expedient and no direct nexus with borrowings was proved. Weighted deduction for scientific research was not confined to DSIR certification where eligible expenditure was genuinely incurred, while product registration costs were held revenue in nature. Section 14A disallowance could not exceed exempt income or be duplicated in book profit, hedging derivative loss was business loss, and doctor freebies and belated employees' contribution remained disallowable; bonus payment required factual verification.

---

---

Issues: (i) whether corporate guarantee given for an associated enterprise constituted an international transaction warranting transfer pricing adjustment; (ii) whether interest disallowance on alleged diversion of borrowed funds to sister concerns was sustainable; (iii) whether weighted deduction under section 35(2AB) could be restricted by DSIR certification and whether the additional claim on gross R&D expenditure was allowable; (iv) whether product registration expenditure was capital or revenue in nature; (v) whether disallowance under section 14A could exceed exempt income and be again added while computing book profit under section 115JB; (vi) whether foreign exchange derivative loss was speculative loss or business loss; (vii) whether freebies and incentives to doctors were hit by Explanation 1 to section 37(1); (viii) whether employees' contribution to welfare funds deposited belatedly was deductible under section 36(1)(va) read with section 2(24)(x); and (ix) whether bonus payment claimed under section 43B required verification and could be allowed.

Issue (i): whether corporate guarantee given for an associated enterprise constituted an international transaction warranting transfer pricing adjustment.

Analysis: The guarantee was a continuation of an earlier arrangement and no fresh guarantee or additional cost, burden, or economic outflow was shown for the year. The earlier orders in the assessee's own case had already treated the same arrangement as not requiring benchmarking on the facts then prevailing. Judicial consistency also supported the view that a corporate guarantee, in the absence of cost or sacrifice, could not be mechanically equated with a bank guarantee for arm's length pricing.

Conclusion: The transfer pricing adjustment on corporate guarantee was not sustainable and the finding is in favour of the assessee.

Issue (ii): whether interest disallowance on alleged diversion of borrowed funds to sister concerns was sustainable.

Analysis: The advances were found to be commercially expedient and business-related, while the Assessing Officer failed to establish a direct nexus between borrowed funds and the advances. The settled principle is that once business nexus and commercial expediency are shown, the Revenue cannot substitute its own judgment for that of the businessman. A further presumption arises where sufficient interest-free funds are available.

Conclusion: The disallowance under section 36(1)(iii) was rightly deleted and the issue is in favour of the assessee.

Issue (iii): whether weighted deduction under section 35(2AB) could be restricted by DSIR certification and whether the additional claim on gross R&D expenditure was allowable.

Analysis: For the relevant year, the pre-amended statutory scheme governed the claim. Earlier binding decisions in the assessee's own case, together with jurisdictional precedent, held that once the research facility is approved and the expenditure is genuinely incurred for scientific research, deduction cannot be curtailed merely because Form 3CL reflects a different figure. The additional claim on contract research receipts was also allowed because the provision does not impose a restriction that deduction is confined only to the amount certified in Form 3CL.

Conclusion: The weighted deduction claim, including the additional claim, was allowable and the issue is in favour of the assessee.

Issue (iv): whether product registration expenditure was capital or revenue in nature.

Analysis: The expenditure was incurred to obtain foreign regulatory approvals needed to market pharmaceutical products. It was recurring, operational, and regulatory in character, and did not create any independent capital asset or proprietary right. The mere possibility of benefit extending beyond one year did not convert an otherwise business expenditure into capital expenditure.

Conclusion: The product registration expenditure was allowable as revenue expenditure and the issue is in favour of the assessee.

Issue (v): whether disallowance under section 14A could exceed exempt income and be again added while computing book profit under section 115JB.

Analysis: The disallowance under section 14A is confined to expenditure actually incurred in relation to exempt income and cannot exceed the exempt income earned. The MAT adjustment under section 115JB must be computed independently and cannot mechanically import the section 14A computation. Adding the same amount again under section 115JB would amount to impermissible duplication.

Conclusion: The restriction of the disallowance and deletion of the MAT adjustment were correct and the issue is in favour of the assessee.

Issue (vi): whether foreign exchange derivative loss was speculative loss or business loss.

Analysis: The contracts were entered into to hedge genuine foreign currency exposure arising from import-export business. Where derivative contracts are intended to mitigate business risk and are integrally connected with business operations, the resulting loss is a normal business loss and not speculative loss. The Revenue failed to show that the transactions were independent speculative ventures.

Conclusion: The foreign exchange fluctuation loss was allowable as business loss and the issue is in favour of the assessee.

Issue (vii): whether freebies and incentives to doctors were hit by Explanation 1 to section 37(1).

Analysis: Expenditure incurred in providing prohibited freebies to medical practitioners is disallowable under Explanation 1 to section 37(1). The binding law treats such spend as barred by law, and the CBDT circular was only declaratory of that position.

Conclusion: The disallowance was rightly sustained and the issue is against the assessee.

Issue (viii): whether employees' contribution to welfare funds deposited belatedly was deductible under section 36(1)(va) read with section 2(24)(x).

Analysis: Employees' contribution is governed by section 36(1)(va) and must be deposited within the due date prescribed under the relevant welfare enactment. Payment before filing the return does not cure the default. The later payment did not satisfy the statutory condition for deduction.

Conclusion: The disallowance was correctly sustained and the issue is against the assessee.

Issue (ix): whether bonus payment claimed under section 43B could be allowed without verification.

Analysis: Deduction under section 43B depends on actual payment and requires factual verification of payment within the prescribed time. Since the supporting material needed verification, the matter was restored for examination by the Assessing Officer.

Conclusion: The claim was not finally allowed or rejected and was remitted for verification.

Final Conclusion: The Revenue's appeal failed in full, while the assessee obtained relief on the major disputed additions, with one bonus-related claim sent back for verification.

Ratio Decidendi: Corporate guarantee without demonstrated cost or economic sacrifice is not automatically benchmarkable; interest cannot be disallowed where advances are commercially expedient and supported by own funds; weighted deduction under section 35(2AB) cannot be curtailed merely by DSIR quantification where genuine eligible expenditure is shown; section 14A disallowance cannot exceed exempt income nor be duplicated under MAT; genuine hedging losses are business losses; and statutory prohibitions under section 37(1) and the employee-contribution rules must be strictly enforced.

---